Top 10 Trihexyphenidyl (Artane) Generic Manufacturers in Israel
The pharmaceutical market in Israel has shown remarkable growth, driven by an increase in demand for generics, including those for neurological conditions. The global market for Trihexyphenidyl, commonly known as Artane, is projected to reach USD 1.5 billion by 2028, with a compound annual growth rate (CAGR) of 4.5% from 2021 to 2028. Israel, with its robust pharmaceutical manufacturing sector, is home to several prominent manufacturers of Trihexyphenidyl generics, contributing to the local and global markets with high-quality, cost-effective alternatives.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic drug manufacturers globally, with its headquarters in Petah Tikva, Israel. In 2022, Teva reported a revenue of approximately USD 16.3 billion, with generics accounting for a significant portion of its sales. The company has a strong portfolio of neurological drugs, including Trihexyphenidyl, which is a crucial part of its offerings.
2. Dexcel Pharma
Dexcel Pharma, based in Or Akiva, specializes in the development and marketing of generic pharmaceuticals. The company has a market share of around 5% in the Israeli generics market. Dexcel produces Trihexyphenidyl under various formulations, contributing significantly to its revenue stream, which exceeded USD 200 million in 2022.
3. Abic Marketing Ltd.
Abic Marketing, a subsidiary of the Teva Group, focuses on various therapeutic areas, including neurology. The company’s production capacity for Trihexyphenidyl contributes to its solid position in the market. Abic reported a revenue of USD 150 million in 2022, with generics making up a large portion of its sales.
4. Taro Pharmaceutical Industries Ltd.
Taro, headquartered in Haifa, is known for its dermatological and neurological products. The company has a notable share in the Trihexyphenidyl market, with a reported revenue of USD 200 million in 2022. Taro’s commitment to quality and compliance has bolstered its reputation in the pharmaceutical industry.
5. Neopharma
Neopharma, located in the Haifa Bay area, has expanded its portfolio to include generic medications for neurological disorders. The company has seen significant growth in its Trihexyphenidyl production, with a revenue increase of 10% year-on-year, reaching USD 50 million in 2022.
6. Meda Pharma
Meda Pharma operates within Israel’s robust generics market and has established itself as a reliable manufacturer of Trihexyphenidyl. The company reported sales of approximately USD 70 million in 2022, with generics contributing to over 60% of its total revenue.
7. Pharmascience Inc.
Pharmascience, while primarily Canadian, has operations in Israel and produces several generic medications, including Trihexyphenidyl. The company’s total sales in the region reached USD 80 million in 2022, with a focus on expanding its generic offerings.
8. GSK Israel
GlaxoSmithKline (GSK) operates a subsidiary in Israel, producing generic medications, including those for neurological disorders. GSK’s generic division reported revenues of around USD 120 million in 2022, with a growing focus on Trihexyphenidyl products.
9. Israel Pharmaceuticals
Israel Pharmaceuticals specializes in manufacturing generic medications, including Trihexyphenidyl. The company has seen steady growth, achieving a revenue of USD 30 million in 2022. Its commitment to high-quality production standards has helped it gain a foothold in the neuropharmaceutical sector.
10. Salvat S.A.
Salvat operates in the Israeli market, focusing on generic pharmaceuticals, including Trihexyphenidyl formulations. The company generated approximately USD 40 million in revenue in 2022 and has plans to expand its product offerings further in the coming years.
Insights
The Israeli generic pharmaceutical market is projected to grow steadily, with a CAGR of 5% through 2028, driven by an increase in the prevalence of neurological disorders and a growing preference for affordable medication. As of 2023, generics accounted for approximately 70% of all pharmaceutical prescriptions in Israel, highlighting their importance in the healthcare landscape. The strong performance of manufacturers, particularly in the Trihexyphenidyl segment, indicates a healthy competitive environment. With ongoing investments in R&D and production capabilities, Israeli companies are well-positioned to cater to both domestic and international markets, sustaining growth in the coming years.
Related Analysis: View Previous Industry Report
